A Conversation about the Phase III SENTRY Trial for Myelofibrosis with Dr. John Mascarenhas
SpotifyIn this HealthTree for Myelofibrosis podcast episode, we spoke with Dr. John Mascarenhas about the SENTRY Trial (NCT04562389). Dr. Mascarenhas is the principal investigator on this global, phase III clinical trial, which is looking at combining the JAK2 inhibitor Ruxolitinib with the XPO1 inhibitor Selinexor for myelofibrosis patients who have not previously been on a JAK inhibitor. The trial is actively enrolling 350 patients and aims to report top-line results in the second half of 2025.
Both Ruxolitinib and Selinexor are FDA-approved therapies. Ruxolitinib is approved for use in the treatment of myelofibrosis, while selinexor is currently approved for the management of other hematologic malignancies. This trial is looking to see if combining ruxolitinib with selinexor provides a better outcome for patients than ruxolitinib alone. People who participate in this trial will receive ruxolitinib+selinexor or ruxolitinib+, a placebo, meaning everyone participating in the study will receive ruxolitinib. In early phase I testing, combining the two therapies demonstrated a favorable safety profile with no new adverse signals.
The two primary metrics evaluated in this study are spleen reduction and total symptom burden reduction. Participants in this trial may have increased monitoring and testing during the duration of the study but, importantly, should not pay more for their treatment or care by participating in this study. Primary outcomes of the trial will be evaluated at 24 weeks but patients will be followed for an extended duration. Dr. Mascarenhas emphasizes that safety is at the forefront of all clinical trials.
Dr. Mascarenhas recommends that anyone eligible or interested in their trial speak with their doctor about it.
Dalton Bean
Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
John Mascarenhas, MD
John Mascarenhas, MD, is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai. Dr. Mascarenhas is the Director of the Center of Excellence for Blood Cancers and Myeloid Disorders, directs the Adult Leukemia Program, and is a member of The Tisch Cancer Institute. His clinical and research focus centers around myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). Throughout his illustrative career, Dr. Mascarenhas has published over 275 papers, is the principal investigator for the National Cancer Institute sponsored Myeloproliferative Disease Research Consortium, and has served as principal investigator or study chair on numerous clinical trials geared toward innovative treatment approaches for MPNs and AML. Dr. Mascarenhas is widely recognized for his work in MPNs and is often invited to speak at conferences for his expertise in the field.
